Increased bone formation in mice lacking apolipoprotein E

Journal of Bone and Mineral Research

Volumn 20, Issue 2, 2005, Pages 274-282

  Schilling, Arndt F ^a   Schinke, Thorsten ^a   Münch, Christian ^a   Gebauer, Matthias ^a   Niemeier, Andreas ^a   Priemel, Matthias ^a   Streichert, Thomas ^a   Rueger, Johannes M ^a   Amling, Michael ^a  

^a University of Medical School Hamburg Eppendorf   (Germany)

Author keywords

carboxylation; Apolipoprotein E; Bone formation; Osteocalcin; Vitamin K

Indexed keywords

APOLIPOPROTEIN E; BONE MORPHOGENETIC PROTEIN; CHOLESTEROL; COLLAGEN; HYDROXYAPATITE; IODINE 125; LIPOPROTEIN; OSTEOCALCIN;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE RADIOGRAPHY; BONE REMODELING; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CHROMATOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; MINERALIZATION; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PHENOTYPE; RADIOIMMUNOASSAY; RNA ISOLATION;

ALLELES; ANIMALS; ANIMALS, NEWBORN; APOLIPOPROTEINS E; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; BONE RESORPTION; CHOLESTEROL; COLLAGEN; DURAPATITE; GENOME; LIPOPROTEINS; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOCALCIN; PHENOTYPE; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 12544252695     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.041101     Document Type: Article

References (54)

1. Brown SA, Rosen CJ 2003 Osteoporosis. Med Clin North Am 87:1039-1063.
2. Harada S, Rodan GA 2003 Control of osteoblast function and regulation of bone mass. Nature 423:349-353.
3. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R 2001 TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 20:2254-2272.
4. Daluiski A, Engstrand T, Bahamonde ME, Gamer LW, Agius E, Stevenson SL, Cox K, Rosen V, Lyons KM 2001 Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27:84-88.
5. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19.
6. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523.
7. Patel MS, Karsenty G 2002 Regulation of bone formation and vision by LRP5. N Engl J Med 346:1572-1574.
8. Miao D, He B, Karaplis AC, Goltzman D 2002 Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest 109:1173-1182.
9. Cornish J, Gallon KE, Lin CQ, Xiao CL, Gamble GD, Cooper GJ, Reid IR 1999 Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J Bone Miner Res 14:1302-1309.
10. Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel RF 2002 Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 110:1849-1857.
11. Spelsberg TC, Subramaniam M, Riggs BL, Khosla S 1999 The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol 13:819-828.
12. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100:197-207.
13. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317.
14. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC 2004 β-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 19:19-24.
15. Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, McClung M, Hosking D, Yates AJ, Christiansen C 1999 Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 14:1622-1627.
16. Beisiegel U, Spector AA 2001 Bone: A forgotten organ in lipidology? Curr Opin Lipidol 13:239-240.
17. Bauer DC 2002 HMG CoA reductase inhibitors and the skeleton: A comprehensive review. Osteoporos Int 14:273-282.
18. Panda S, Sato TK, Hampton GM, Hogenesch JB 2003 An array of insights: Application of DNA chip technology in the study of cell biology. Trends Cell Biol 13:151-156.
19. Roman-Roman S, Garcia T, Jackson A, Theilhaber J, Rawadi G, Connolly T, Spinella-Jaegle S, Kawai S, Courtois B, Bushnell S, Auberval M, Call K, Baron R 2003 Identification of genes regulated during osteoblastic differentiation by genome-wide expression analysis of mouse calvaria primary osteoblasts in vitro. Bone 32:474-482.
20. McCauley LK 2001 Transgenic mouse models of metabolic bone disease. Curr Opin Rheumatol 13:316-325.
21. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G 1996 Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452.
22. Rajagopalan D 2003 A comparison of statistical methods for analysis of high density oligonucleotide array data. Bioinformatics 19:1469-1476.
23. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB 1999 Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of a normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses. Endocrinology 140:4982-4987.
24. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott, SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols and units. J Bone Miner Res 2:595-610.
25. Heeren J, Niemeier A, Merkel M, Beisiegel U 2002 Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo. J Mol Med 80:576-584.
26. Aubin JE 1998 Advances in the osteoblast lineage. Biochem Cell Biol 76:899-910.
27. Niemeier A, Kassem K, Toedter K, Wendt D, Ruether W, Beisiegel U, Heeren J 2004 Expression of LRP1 by human osteoblasts: A mechanism for the delivery of lipoproteins and dietary vitamin K to bone. J Bone Miner Res 20:283-293.
28. Newman P, Bonello F, Wierzbicki AS, Lumb P, Savidge GF, Shearer MJ 2002 The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: Role of heparan sulfate proteoglycans and apolipoprotein E. J Bone Miner Res 17:426-433.
29. Binkley NC, Krueger DC, Kawahara TN, Engelke JA, Chappell RJ, Suttie JW 2002 A high phylloquinone intake is required to achieve maximal osteocalcin gamma carboxylation. Am J Clin Nutr 76:1055-1060.
30. Weisgraber KH 1994 Apolipoprotein E: Structure-function relationships. Adv Protein Chem 45:249-302.
31. Weisgraber KH, Rall SC Jr, Mahley RW 1981 Human E apo-protein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 256:9077-9083.
32. Breslow JL, Zannis VI, SanGiacomo TR, Third JL, Tracy T, Glueck CJ 1982 Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res 23:1224-1235.
33. Havekes L, de Wit E, Leuven JG, Klasen E, Utermann G, Weber W, Beisiegel U 1986 Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum Genet 73:157-163.
34. Mahley RW, Rail SC Jr 1995 Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Sriver CR, Beaudet AL, Sly WS, Valle D (eds.) The Metabolic and Molecular Basis of Inherited Disease, 7th ed. McGraw-Hill, New York, NY, USA, pp. 1953-1980
35. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB Jr 1986 Familial apolipoprotein E deficiency. J Clin Invest 78:1206-1219.
36. Zhang SH, Reddick RL, Piedrahita JA, Maeda N 1992 Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468-471.
37. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL 1992 Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353.
38. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA 1993 Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
39. Kohlmeier M, Saupe J, Schaefer K, Asmus G 1998 Bone fracture history and prospective bone fracture risk of hemodialysis patients are related to apolipoprotein E genotype. Calcif Tissue Int 62:278-281.
40. Shiraki M, Shiraki Y, Aoki C, Hosoi T, Inoue S, Kaneki M, Ouchi Y 1997 Association of bone mineral density with apolipoprotein E phenotype. J Bone Miner Res 12:1438-1445.
41. Dick IM, Devine A, Marangou A, Dhaliwal SS, Laws S, Martins RN, Prince RL 2002 Apolipoprotein E4 is associated with reduced calcaneal quantitative ultrasound measurements and bone mineral density in elderly women. Bone 31:497-502.
42. Sennels HP, Sand JC, Madsen B, Lauritzen JB, Fenger M, Jorgensen HL 2003 Association between polymorphisms of apolipoprotein E, bone mineral density of the lower forearm, quantitative ultrasound of the calcaneus and osteoporotic fractures in postmenopausal women with hip or lower forearm fracture. Scand J Clin Lab Invest 63:247-258.
43. Stulc T, Ceska R, Horinek A, Stepan J 2000 Bone mineral density in patients with apolipoprotein E type 2/2 and 4/4 genotype. Physiol Res 49:435-439.
44. Heikkinen AM, Kroger H, Niskanen L, Komulainen MH, Ryynanen M, Parviainen MT, Tuppurainen MT, Honkanen R, Saarikoski S 2000 Does apolipoprotein E genotype relate to BMD and bone markers in postmenopausal women? Maturitas 34:33-41.
45. Bachner D, Schroder D, Betat N, Ahrens M, Gross G 1999 Apolipoprotein E (ApoE), a Bmp-2 (bone morphogenetic protein) upregulated gene in mesenchymal progenitors (C3H10T1/2), is highly expressed in murine embryonic development. Biofactors 9:11-17.
46. Linton MF, Hasty AH, Babaev VR, Fazio S 1998 Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J Clin Invest 101:1726-1736.
47. Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, Hui DY, Mahley RW, Gebicke-Haerter PJ, Ignatius MJ 1989 A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 83:1015-1031.
48. Philip WJ, Martin JC, Richardson JM, Reid DM, Webster J, Douglas AS 1995 Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 88:635-640.
49. Sato Y, Honda Y, Kunoh H, Oizumi K 1997 Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke 28:2390-2394.
50. Rosen HN, Maitland LA, Suttie JW, Manning WJ, Glynn RJ, Greenspan SL 1993 Vitamin K and maintenance of skeletal integrity in adults. Am J Med 94:62-68.
51. Jamal SA, Browner WS, Bauer DC, Cummings SR 1998 Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 128:829-832.
52. Howe AM, Webster WS 2000 Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol 81:51-56.
53. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G 1997 Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78-81.
54. Schinke T, McKee MD, Karsenty G 1999 Extracellular matrix calcification: Where is the action? Nat Genet 21:150-151.